We use cookies to ensure that we give you the best experience on our website. By continuing to browse the site you are agreeing to our use of cookies. If you would like to know more please click here.

Latest News

MRCT and Cyclofluidic Announce Successful Collaboration


Cyclofluidic has been collaborating with MRCT to develop advanced tools against important cancer target hepsin. The collaboration used the Cyclofluidic CyclOps integrated synthesis and screen platform to optimise compounds for potency against hepsin and selectivity against uPA. The tool compounds are now being tested by MRCT collaborators in the University of Helsinki to further validate this promising target. The full press release can be found here:


Posted by Elizabeth Date 24/03/2015